modafinil has been researched along with MS (Multiple Sclerosis) in 37 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amantadine, modafinil, and methylphenidate were not superior to placebo in improving multiple sclerosis fatigue and caused more frequent adverse events." | 9.41 | Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. ( Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021) |
| " Eligible participants with MS and significant fatigue severity are randomly assigned (1:1:1) to received either CBT, modafinil, or a combination of CBT and modafinil for 12 weeks." | 9.30 | A randomized pragmatic trial of telephone-delivered cognitive behavioral-therapy, modafinil, and combination therapy of both for fatigue in multiple sclerosis: The design of the "COMBO-MS" trial. ( Alschuler, KN; Braley, TJ; Ehde, DM; Kratz, AL; Kulkarni, S; Little, R; Pickup, K; von Geldern, G, 2019) |
| "The study is a randomized, placebo-controlled, crossover, four-sequence, four-period, double-blind, multicenter trial of three commonly used medications for the treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS." | 9.27 | Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. ( Nourbakhsh, B; Revirajan, N; Waubant, E, 2018) |
| "To assess the efficacy of modafinil for the treatment of new learning and memory deficits and fatigue in multiple sclerosis." | 9.22 | Cognitive effects of modafinil in patients with multiple sclerosis: A clinical trial. ( Chiaravalloti, ND; DeLuca, J; Elovic, E; Ford-Johnson, L; Lengenfelder, J; Zhang, J, 2016) |
| "One month treatment with amantadine improved fatigue in patients with relapsing-remitting MS as evaluated by MFIS." | 9.17 | Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study. ( Ledinek, AH; Rot, U; Sajko, MC, 2013) |
| "Examine the efficacy of armodafinil in improving cognition in patients with multiple sclerosis (MS)." | 9.16 | Impact of armodafinil on cognition in multiple sclerosis: a randomized, double-blind crossover pilot study. ( Brown, A; Bruce, J; Hancock, L; Henkelman, E; Lynch, S; Roberg, B, 2012) |
| "To reassess the effect of modafinil, a wakefulness-promoting artificial psychostimulant, on fatigue and neuropsychological measures in patients with multiple sclerosis." | 9.15 | HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. ( Broemel, F; Daumer, M; Heesen, C; Möller, F; Neuhaus, A; Poettgen, J, 2011) |
| "To investigate the effects of Modafinil on focused attention, motor function and motor excitability in patients with multiple sclerosis (MS) and fatigue." | 9.14 | Modafinil effects in multiple sclerosis patients with fatigue. ( Heesen, C; Lange, R; Liepert, J; Volkmer, M, 2009) |
| "There was no improvement of fatigue in patients with multiple sclerosis treated with modafinil vs placebo according to the Modified Fatigue Impact Scale." | 9.11 | Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. ( Clanet, M; Confavreux, C; Debouverie, M; Edan, G; Lubetzki, C; Moreau, T; Pelletier, J; Rumbach, L; Stankoff, B; Waubant, E, 2005) |
| "These data suggest that 200 mg/day modafinil significantly improves fatigue and is well tolerated in patients with MS." | 9.10 | Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. ( Blumenfeld, AM; Lynn, DJ; Nagaraja, HN; Pollak, CP; Rammohan, KW; Rosenberg, JH, 2002) |
| "Our meta-analysis showed that modafinil was an effective pharmacologic therapy for MS fatigue." | 8.98 | Meta-analysis of the efficacy of modafinil versus placebo in the treatment of multiple sclerosis fatigue. ( Jie, C; Kuiqing, L; Shangyan, H; Weixiong, L; Yumin, X, 2018) |
| "Based on the available data, use of modafinil for the treatment of MS-related fatigue has demonstrated benefit in all uncontrolled studies but has conflicting results from 2 controlled studies." | 8.86 | Modafinil for the treatment of multiple sclerosis-related fatigue. ( Brown, JN; Howard, CA; Kemp, DW, 2010) |
| "Modafinil (Provigil) is approved for treating excessive daytime sleepiness associated with narcolepsy, for shift-work sleep disorder, and as an adjunctive treatment in patients with obstructive sleep apnea syndrome who have residual daytime sleepiness despite optimal treatment with continuous positive airway pressure." | 8.84 | Modafinil in the treatment of excessive daytime sleepiness. ( Foldvary-Schaefer, N; Valentino, RM, 2007) |
| "We audited the patient perceived effectiveness of modafinil when used in clinical practice in a carefully selected group of patients with typical MS fatigue." | 7.76 | Modafinil for multiple sclerosis fatigue: does it work? ( Hobart, JC; Littleton, ET; Palace, J, 2010) |
| "It was the aim of this study to compare fatigue observed in different neurological pathologies, to evaluate the tolerability to modafinil, and to describe changes in subjective fatigue." | 7.75 | Effect of modafinil on subjective fatigue in multiple sclerosis and stroke patients. ( Annoni, JM; Bassetti, C; Brioschi, A; Gramigna, S; Ruffieux, C; Schluep, M; Staub, F; Werth, E, 2009) |
| "To evaluate the value of visual and auditory P300 for predicting the response of multiple sclerosis-related fatigue to modafinil treatment, 33 patients were treated with 100 mg modafinil once daily for 4 weeks, following a 4-week baseline phase and an optional 8-week extension phase." | 7.74 | P300 and treatment effect of modafinil on fatigue in multiple sclerosis. ( D'hooghe, MB; De Deyn, PP; Despontin, M; Kos, D; Nagels, G; Vleugels, L, 2007) |
| "To establish the efficacy, safety and appropriate dose of modafinil in the treatment of fatigue and sleepiness in patients with multiple sclerosis." | 7.71 | Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. ( Maida, EM; Rupp, M; Schwarz, S; Zifko, UA; Zipko, HT, 2002) |
| "Fatigue is a common and distressing symptom of MS which is unrelated to its clinical form, stage of development, the degree of disability, or the lesion load on magnetic resonance imaging." | 6.78 | Association of a deficit of arousal with fatigue in multiple sclerosis: effect of modafinil. ( Bibani, RH; Bradshaw, CM; Constantinescu, CS; Langley, RW; Niepel, G; Szabadi, E; Vilisaar, J, 2013) |
| "Amantadine, modafinil, and methylphenidate were not superior to placebo in improving multiple sclerosis fatigue and caused more frequent adverse events." | 5.41 | Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. ( Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021) |
| "Fatigue is one of the most frequent and disabling symptoms in multiple sclerosis (MS) patients." | 5.32 | [Modafinil and fatigue in multiple sclerosis]. ( Montalbán, X; Téllez, N, 2004) |
| " Eligible participants with MS and significant fatigue severity are randomly assigned (1:1:1) to received either CBT, modafinil, or a combination of CBT and modafinil for 12 weeks." | 5.30 | A randomized pragmatic trial of telephone-delivered cognitive behavioral-therapy, modafinil, and combination therapy of both for fatigue in multiple sclerosis: The design of the "COMBO-MS" trial. ( Alschuler, KN; Braley, TJ; Ehde, DM; Kratz, AL; Kulkarni, S; Little, R; Pickup, K; von Geldern, G, 2019) |
| "The study is a randomized, placebo-controlled, crossover, four-sequence, four-period, double-blind, multicenter trial of three commonly used medications for the treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS." | 5.27 | Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. ( Nourbakhsh, B; Revirajan, N; Waubant, E, 2018) |
| "To assess the efficacy of modafinil for the treatment of new learning and memory deficits and fatigue in multiple sclerosis." | 5.22 | Cognitive effects of modafinil in patients with multiple sclerosis: A clinical trial. ( Chiaravalloti, ND; DeLuca, J; Elovic, E; Ford-Johnson, L; Lengenfelder, J; Zhang, J, 2016) |
| "One month treatment with amantadine improved fatigue in patients with relapsing-remitting MS as evaluated by MFIS." | 5.17 | Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study. ( Ledinek, AH; Rot, U; Sajko, MC, 2013) |
| "Examine the efficacy of armodafinil in improving cognition in patients with multiple sclerosis (MS)." | 5.16 | Impact of armodafinil on cognition in multiple sclerosis: a randomized, double-blind crossover pilot study. ( Brown, A; Bruce, J; Hancock, L; Henkelman, E; Lynch, S; Roberg, B, 2012) |
| "To reassess the effect of modafinil, a wakefulness-promoting artificial psychostimulant, on fatigue and neuropsychological measures in patients with multiple sclerosis." | 5.15 | HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. ( Broemel, F; Daumer, M; Heesen, C; Möller, F; Neuhaus, A; Poettgen, J, 2011) |
| "To investigate the effects of Modafinil on focused attention, motor function and motor excitability in patients with multiple sclerosis (MS) and fatigue." | 5.14 | Modafinil effects in multiple sclerosis patients with fatigue. ( Heesen, C; Lange, R; Liepert, J; Volkmer, M, 2009) |
| "There was no improvement of fatigue in patients with multiple sclerosis treated with modafinil vs placebo according to the Modified Fatigue Impact Scale." | 5.11 | Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. ( Clanet, M; Confavreux, C; Debouverie, M; Edan, G; Lubetzki, C; Moreau, T; Pelletier, J; Rumbach, L; Stankoff, B; Waubant, E, 2005) |
| "These data suggest that 200 mg/day modafinil significantly improves fatigue and is well tolerated in patients with MS." | 5.10 | Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. ( Blumenfeld, AM; Lynn, DJ; Nagaraja, HN; Pollak, CP; Rammohan, KW; Rosenberg, JH, 2002) |
| "Our meta-analysis showed that modafinil was an effective pharmacologic therapy for MS fatigue." | 4.98 | Meta-analysis of the efficacy of modafinil versus placebo in the treatment of multiple sclerosis fatigue. ( Jie, C; Kuiqing, L; Shangyan, H; Weixiong, L; Yumin, X, 2018) |
| " We included studies investigating pemoline and modafinil in participants with multiple sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue in meta-analysis." | 4.91 | Pharmacological treatments for fatigue associated with palliative care. ( Cuhls, H; Minton, O; Mücke, M; Peuckmann-Post, V; Radbruch, L; Stone, P, 2015) |
| " Studies investigating amantadine, pemoline, and modafinil in participants with Multiple Sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue could be used for meta-analysis." | 4.86 | Pharmacological treatments for fatigue associated with palliative care. ( Elsner, F; Krumm, N; Peuckmann, V; Radbruch, L; Trottenberg, P, 2010) |
| "Based on the available data, use of modafinil for the treatment of MS-related fatigue has demonstrated benefit in all uncontrolled studies but has conflicting results from 2 controlled studies." | 4.86 | Modafinil for the treatment of multiple sclerosis-related fatigue. ( Brown, JN; Howard, CA; Kemp, DW, 2010) |
| "Modafinil (Provigil) is approved for treating excessive daytime sleepiness associated with narcolepsy, for shift-work sleep disorder, and as an adjunctive treatment in patients with obstructive sleep apnea syndrome who have residual daytime sleepiness despite optimal treatment with continuous positive airway pressure." | 4.84 | Modafinil in the treatment of excessive daytime sleepiness. ( Foldvary-Schaefer, N; Valentino, RM, 2007) |
| "We audited the patient perceived effectiveness of modafinil when used in clinical practice in a carefully selected group of patients with typical MS fatigue." | 3.76 | Modafinil for multiple sclerosis fatigue: does it work? ( Hobart, JC; Littleton, ET; Palace, J, 2010) |
| "It was the aim of this study to compare fatigue observed in different neurological pathologies, to evaluate the tolerability to modafinil, and to describe changes in subjective fatigue." | 3.75 | Effect of modafinil on subjective fatigue in multiple sclerosis and stroke patients. ( Annoni, JM; Bassetti, C; Brioschi, A; Gramigna, S; Ruffieux, C; Schluep, M; Staub, F; Werth, E, 2009) |
| "To evaluate the value of visual and auditory P300 for predicting the response of multiple sclerosis-related fatigue to modafinil treatment, 33 patients were treated with 100 mg modafinil once daily for 4 weeks, following a 4-week baseline phase and an optional 8-week extension phase." | 3.74 | P300 and treatment effect of modafinil on fatigue in multiple sclerosis. ( D'hooghe, MB; De Deyn, PP; Despontin, M; Kos, D; Nagels, G; Vleugels, L, 2007) |
| "To establish the efficacy, safety and appropriate dose of modafinil in the treatment of fatigue and sleepiness in patients with multiple sclerosis." | 3.71 | Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. ( Maida, EM; Rupp, M; Schwarz, S; Zifko, UA; Zipko, HT, 2002) |
| "Fatigue is a common and distressing symptom of MS which is unrelated to its clinical form, stage of development, the degree of disability, or the lesion load on magnetic resonance imaging." | 2.78 | Association of a deficit of arousal with fatigue in multiple sclerosis: effect of modafinil. ( Bibani, RH; Bradshaw, CM; Constantinescu, CS; Langley, RW; Niepel, G; Szabadi, E; Vilisaar, J, 2013) |
| "Fatigue is the most common and debilitating symptom in multiple sclerosis (MS) and is believed to be distinctly different from fatigue seen in other chronic conditions." | 2.48 | Fatigue in multiple sclerosis - a brief review. ( Constantinescu, CS; Gran, B; Induruwa, I, 2012) |
| "Fatigue is the most common symptom of MS and is associated with a reduced quality of life." | 2.42 | Management of fatigue in patients with multiple sclerosis. ( Zifko, UA, 2004) |
| "Fatigue is among the most common, yet least understood, symptoms of multiple sclerosis (MS) [1." | 2.41 | Fatigue in multiple sclerosis. ( Christodoulou, C; Krupp, LB, 2001) |
| "The Fatigue Impact Scale for Daily Use (D-FIS) is an eight-item instrument designed to measure subjective daily experience of fatigue." | 1.34 | Impact of fatigue in multiple sclerosis: the Fatigue Impact Scale for Daily Use (D-FIS). ( Antigüedad, AR; Benito-León, J; de Andrés, C; Frades, B; Huete-Antón, B; Martínez-Ginés, ML; Martínez-Martín, P; Meca-Lallana, JE; Rodríguez-García, E; Ruiz-Martínez, J, 2007) |
| "Fatigue is one of the most frequent and disabling symptoms in multiple sclerosis (MS) patients." | 1.32 | [Modafinil and fatigue in multiple sclerosis]. ( Montalbán, X; Téllez, N, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (51.35) | 29.6817 |
| 2010's | 14 (37.84) | 24.3611 |
| 2020's | 4 (10.81) | 2.80 |
| Authors | Studies |
|---|---|
| Cocco, E | 1 |
| Fadda, P | 1 |
| Palotai, M | 1 |
| Pintye, D | 1 |
| Glanz, B | 1 |
| Chitnis, T | 1 |
| Guttmann, CRG | 1 |
| Kratz, AL | 1 |
| Alschuler, KN | 1 |
| Ehde, DM | 1 |
| von Geldern, G | 1 |
| Little, R | 1 |
| Kulkarni, S | 1 |
| Pickup, K | 1 |
| Braley, TJ | 1 |
| Nourbakhsh, B | 2 |
| Revirajan, N | 2 |
| Morris, B | 1 |
| Cordano, C | 1 |
| Creasman, J | 1 |
| Manguinao, M | 1 |
| Krysko, K | 1 |
| Rutatangwa, A | 1 |
| Auvray, C | 1 |
| Aljarallah, S | 1 |
| Jin, C | 1 |
| Mowry, E | 1 |
| McCulloch, C | 1 |
| Waubant, E | 3 |
| Bourdette, D | 1 |
| Shangyan, H | 1 |
| Kuiqing, L | 1 |
| Yumin, X | 1 |
| Jie, C | 1 |
| Weixiong, L | 1 |
| Rubin, SM | 1 |
| Ledinek, AH | 1 |
| Sajko, MC | 1 |
| Rot, U | 1 |
| Mücke, M | 1 |
| Cuhls, H | 1 |
| Peuckmann-Post, V | 1 |
| Minton, O | 1 |
| Stone, P | 1 |
| Radbruch, L | 2 |
| Ford-Johnson, L | 1 |
| DeLuca, J | 1 |
| Zhang, J | 1 |
| Elovic, E | 1 |
| Lengenfelder, J | 1 |
| Chiaravalloti, ND | 1 |
| Lange, R | 1 |
| Volkmer, M | 1 |
| Heesen, C | 2 |
| Liepert, J | 1 |
| Brioschi, A | 1 |
| Gramigna, S | 1 |
| Werth, E | 1 |
| Staub, F | 1 |
| Ruffieux, C | 1 |
| Bassetti, C | 1 |
| Schluep, M | 1 |
| Annoni, JM | 1 |
| Littleton, ET | 1 |
| Hobart, JC | 1 |
| Palace, J | 1 |
| Brown, JN | 1 |
| Howard, CA | 1 |
| Kemp, DW | 1 |
| Peuckmann, V | 1 |
| Elsner, F | 1 |
| Krumm, N | 1 |
| Trottenberg, P | 1 |
| Möller, F | 1 |
| Poettgen, J | 1 |
| Broemel, F | 1 |
| Neuhaus, A | 1 |
| Daumer, M | 1 |
| Niepel, G | 1 |
| Bibani, RH | 1 |
| Vilisaar, J | 1 |
| Langley, RW | 1 |
| Bradshaw, CM | 1 |
| Szabadi, E | 1 |
| Constantinescu, CS | 2 |
| Induruwa, I | 1 |
| Gran, B | 1 |
| Bruce, J | 1 |
| Hancock, L | 1 |
| Roberg, B | 1 |
| Brown, A | 1 |
| Henkelman, E | 1 |
| Lynch, S | 1 |
| Zifko, UA | 2 |
| Rupp, M | 1 |
| Schwarz, S | 1 |
| Zipko, HT | 1 |
| Maida, EM | 1 |
| Téllez, N | 1 |
| Montalbán, X | 1 |
| Schwid, SR | 1 |
| Murray, TJ | 1 |
| Stankoff, B | 1 |
| Confavreux, C | 1 |
| Edan, G | 1 |
| Debouverie, M | 2 |
| Rumbach, L | 1 |
| Moreau, T | 1 |
| Pelletier, J | 1 |
| Lubetzki, C | 1 |
| Clanet, M | 1 |
| Kraft, GH | 1 |
| Bowen, J | 1 |
| Rammohan, KW | 2 |
| Lynn, DJ | 2 |
| Pittion, S | 1 |
| Boërio, D | 1 |
| Lefaucheur, JP | 1 |
| Hogrel, JY | 1 |
| Créange, A | 1 |
| Nagels, G | 1 |
| D'hooghe, MB | 1 |
| Vleugels, L | 1 |
| Kos, D | 1 |
| Despontin, M | 1 |
| De Deyn, PP | 1 |
| Carrieri, PB | 1 |
| de Leva, MF | 1 |
| Carrieri, M | 1 |
| Buongiorno, M | 1 |
| Benito-León, J | 1 |
| Martínez-Martín, P | 1 |
| Frades, B | 1 |
| Martínez-Ginés, ML | 1 |
| de Andrés, C | 1 |
| Meca-Lallana, JE | 1 |
| Antigüedad, AR | 1 |
| Huete-Antón, B | 1 |
| Rodríguez-García, E | 1 |
| Ruiz-Martínez, J | 1 |
| Valentino, RM | 1 |
| Foldvary-Schaefer, N | 1 |
| Hohlfeld, R | 1 |
| Willoughby, E | 1 |
| Rosenberg, JH | 1 |
| Blumenfeld, AM | 1 |
| Pollak, CP | 1 |
| Nagaraja, HN | 1 |
| Krupp, LB | 1 |
| Christodoulou, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis[NCT03185065] | Phase 3 | 141 participants (Actual) | Interventional | 2017-10-04 | Completed | ||
| A PILOT STUDY OF INTRAVENOUS, SUBANESTHETIC DOSE OF KETAMINE VS PLACEBO, A CROSSOVER DESIGN, FOR MULTIPLE SCLEROSIS RELATED FATIGUE[NCT06064162] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| Feasibility Study of Adjunctive Bright Light Therapy (BLT) for Amelioration of Fatigue in Chinese Cancer Patients Admitted to a Palliative Care Unit[NCT04525924] | 42 participants (Anticipated) | Interventional | 2020-08-01 | Recruiting | |||
| Amantadine for Neuroenhancement in Acute Patients Study - A Prospective Pilot Proof of Concept Phase IIb Study in Intensive and Intermediate Care Unit Patients[NCT05479032] | Phase 2 | 50 participants (Anticipated) | Interventional | 2022-09-30 | Not yet recruiting | ||
| Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients[NCT05319093] | 40 participants (Anticipated) | Observational | 2022-04-30 | Not yet recruiting | |||
| Self-Management Program Based on Physical Exercises for People With Multiple Sclerosis With Mild Neurological Impairment: A Randomized Controlled Trial[NCT02607020] | 100 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | |||
| Multicenter Study, Randomized, Parallel Group Controlled, Testing the Effectiveness of a Behavioral Cognitive Therapy (BCT) vs Usual Local Practice on the Fatigue of Patients With Relapsing Remittent Multiple Sclerosis (RRMS)[NCT03758820] | 105 participants (Actual) | Interventional | 2017-05-31 | Completed | |||
| A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525] | Phase 3 | 59 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Comparison Between the Effects on Fatigue of Aerobic Training Versus Balance Training in Patients With Multiple Sclerosis: a Randomised Crossover Trial.[NCT06051019] | 39 participants (Actual) | Interventional | 2016-02-17 | Completed | |||
| The Effects of EXOPULSE Mollii Suit on Motor Functions in Patients With Multiple Sclerosis (EXOSEP 2)[NCT05857280] | 36 participants (Anticipated) | Interventional | 2023-03-21 | Recruiting | |||
| Continuous Positive Airway Pressure for Fatigue Treatment in Patients With Multiple Sclerosis and Obstructive Sleep Apnea[NCT01563900] | 0 participants (Actual) | Interventional | 2012-02-29 | Withdrawn (stopped due to Was unable to recruit subjects) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Participants will answer yes or no to this question: Taken into consideration the possible benefits and/or disadvantages of this medication, would you choose it, going forward to treat your MS fatigue?. The number of participants who answered Yes to this question is reported here." (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 39 |
| Amantadine | 41 |
| Modafinil | 55 |
| Methylphenidate | 55 |
ESS score during the fifth week of treatment period. The ESS score can range from 0 to 24. The higher the score, the higher that person's average sleep propensity in daily life, or their 'daytime sleepiness'. (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 9.4 |
| Amantadine | 9.3 |
| Modafinil | 8.3 |
| Methylphenidate | 8.8 |
MFIS score during the fifth week of treatment period. The total score of the MFIS ranges from 0 to 84. Higher scores denote more severe fatigue. (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 40.6 |
| Amantadine | 41.3 |
| Modafinil | 39.0 |
| Methylphenidate | 38.6 |
Neuro-QoL Item Bank - Fatigue T score during the fifth week of treatment period. T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Higher T-scores denote more severe fatigue. (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 53.1 |
| Amantadine | 53.0 |
| Modafinil | 52.5 |
| Methylphenidate | 52.0 |
11 reviews available for modafinil and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Treatment of multiple sclerosis fatigue with the synthetic psychoactive drug modafinil.
Topics: Activities of Daily Living; Central Nervous System Stimulants; Fatigue; Humans; Modafinil; Multiple | 2022 |
Meta-analysis of the efficacy of modafinil versus placebo in the treatment of multiple sclerosis fatigue.
Topics: Adult; Benzhydryl Compounds; Cytochrome P-450 CYP3A Inducers; Fatigue; Humans; Middle Aged; Modafini | 2018 |
Management of cognition and fatigue.
Topics: Animals; Antibodies, Monoclonal, Humanized; Benzhydryl Compounds; Cognition Disorders; Depression; D | 2013 |
Pharmacological treatments for fatigue associated with palliative care.
Topics: Adult; Amantadine; Benzhydryl Compounds; Carnitine; Central Nervous System Stimulants; Chronic Disea | 2015 |
Modafinil for the treatment of multiple sclerosis-related fatigue.
Topics: Animals; Benzhydryl Compounds; Fatigue; Humans; Modafinil; Multiple Sclerosis; Randomized Controlled | 2010 |
Pharmacological treatments for fatigue associated with palliative care.
Topics: Adult; Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Humans; Kidney | 2010 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Management of fatigue in patients with multiple sclerosis.
Topics: Amantadine; Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Clinical | 2004 |
[Pathophysiology and treatment of fatigue in multiple sclerosis].
Topics: 4-Aminopyridine; Acute Disease; Amantadine; Amifampridine; Asthenia; Benzhydryl Compounds; Central N | 2006 |
Modafinil in the treatment of excessive daytime sleepiness.
Topics: Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulan | 2007 |
Fatigue in multiple sclerosis.
Topics: Amantadine; Autoimmune Diseases; Benzhydryl Compounds; Brain; Case Management; Central Nervous Syste | 2001 |
11 trials available for modafinil and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
A randomized pragmatic trial of telephone-delivered cognitive behavioral-therapy, modafinil, and combination therapy of both for fatigue in multiple sclerosis: The design of the "COMBO-MS" trial.
Topics: Central Nervous System Stimulants; Cognitive Behavioral Therapy; Combined Modality Therapy; Fatigue; | 2019 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial.
Topics: Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Fatigue; Hum | 2018 |
Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study.
Topics: Acetylcarnitine; Adult; Amantadine; Benzhydryl Compounds; Drug Combinations; Fatigue; Female; Humans | 2013 |
Cognitive effects of modafinil in patients with multiple sclerosis: A clinical trial.
Topics: Adult; Benzhydryl Compounds; Cognition; Cognition Disorders; Cross-Over Studies; Double-Blind Method | 2016 |
Modafinil effects in multiple sclerosis patients with fatigue.
Topics: Adult; Analysis of Variance; Attention; Benzhydryl Compounds; Double-Blind Method; Evoked Potentials | 2009 |
HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis.
Topics: Adult; Benzhydryl Compounds; Double-Blind Method; Fatigue; Female; Humans; Male; Modafinil; Multiple | 2011 |
Association of a deficit of arousal with fatigue in multiple sclerosis: effect of modafinil.
Topics: Adult; Arousal; Autonomic Nervous System; Benzhydryl Compounds; Cardiovascular Agents; Central Nervo | 2013 |
Impact of armodafinil on cognition in multiple sclerosis: a randomized, double-blind crossover pilot study.
Topics: Adult; Benzhydryl Compounds; Cognition; Cognition Disorders; Cross-Over Studies; Double-Blind Method | 2012 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Agents; Fatigue; Female; Human | 2002 |
Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Agents; Fatigue; Female; Human | 2002 |
Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Agents; Fatigue; Female; Human | 2002 |
Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Agents; Fatigue; Female; Human | 2002 |
15 other studies available for modafinil and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Fronto-striatal damage may contribute to resistance to fatigue-lowering medications in multiple sclerosis.
Topics: Anti-Anxiety Agents; Brain; Cross-Sectional Studies; Humans; Modafinil; Multiple Sclerosis; Retrospe | 2023 |
Are drugs for multiple sclerosis fatigue just placebos?
Topics: Amantadine; Double-Blind Method; Fatigue; Humans; Methylphenidate; Modafinil; Multiple Sclerosis; Ph | 2021 |
Effect of modafinil on subjective fatigue in multiple sclerosis and stroke patients.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Fa | 2009 |
Modafinil for multiple sclerosis fatigue: does it work?
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Female; Follow-Up Studies; | 2010 |
Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study.
Topics: Adult; Anxiety; Benzhydryl Compounds; Central Nervous System Stimulants; Dizziness; Fatigue; Female; | 2002 |
[Modafinil and fatigue in multiple sclerosis].
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Clinical Trials as Topic; Fatigue; Humans; | 2004 |
Treating fatigue in patients with MS: one step forward, one step back.
Topics: Amantadine; Aspirin; Benzhydryl Compounds; Central Nervous System; Central Nervous System Stimulants | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorder; Diagnostic Errors; Dos | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Fatigue S | 2005 |
[Fatigue and episodic exhaustion as a feature of multiple sclerosis].
Topics: 4-Aminopyridine; Amantadine; Amifampridine; Benzhydryl Compounds; Fatigue; Humans; Hypnotics and Sed | 2006 |
P300 and treatment effect of modafinil on fatigue in multiple sclerosis.
Topics: Acoustic Stimulation; Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Electroencepha | 2007 |
Modafinil improves primary nocturnal enuresis in multiple sclerosis.
Topics: Adult; Benzhydryl Compounds; Central Nervous System; Central Nervous System Stimulants; Fatigue; Fem | 2007 |
Impact of fatigue in multiple sclerosis: the Fatigue Impact Scale for Daily Use (D-FIS).
Topics: Adolescent; Adult; Aged; Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Dopami | 2007 |
["Fatigue" in multiple sclerosis].
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Clinical Trials as Topic; Dose-Response Rel | 2000 |
Modafinil for fatigue in multiple sclerosis.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Clinical Trials, Phase II as Topic; Fatigue | 2002 |